Poll: Most adults use antibacterial soap, find it useful
WASHINGTON — A poll released by the American Cleaning Institute found that nearly three-quarters of Americans use antibacterial soap, and many of them wouldn’t be happy if the government banned such products.
The poll, which consisted of 1,000 U.S. adults, ages 18 years and older, found that 74% of consumers use antibacterial soap — with 56% of those respondents using them on a regular basis — and deemed antibacterial soap as a preventive measure to avoid the spread of germs.
Additional findings included:
Among moms with children in the household, 75% said would be "angry" if the government took antibacterial soap off the market;
Two-thirds of consumers would be upset if the government took antibacterial soap off the market;
Eighty-four percent of adults do not have any health or environmental concerns about antibacterial soap; and
By an 8-to-1 margin, consumers would prefer to have the choice to buy antibacterial soap rather than removing it from the market based on alleged health and environmental concerns.
The poll followed an urge from special-interest groups for the government to ban the use of antibacterial agents in personal care products, despite overwhelming science demonstrating their safety and effectiveness.
"This poll demonstrates that American consumers want access to soaps that are proven to eliminate germs and help fight infections," said Brian Sansoni, spokesman for the American Cleaning Institute. "These products are used safely and effectively in homes, offices, restaurants, child care centers and thousands of other workplaces every single day."
Impax responds to reports about generic Lipitor
HAYWARD, Calif. — In response to articles that appeared in several media outlets about its generic drug pipeline, drug maker Impax Labs is looking to set the record straight.
The company said several financial websites had reported that Impax had found a way to make a generic version of Pfizer’s cholesterol-lowering drug Lipitor (atorvastatin calcium).
The company said that while it had 98 generic drugs in its development pipeline and had filed for approval for 36 drugs with the Food and Drug Administration, it had not filed an application for a generic version of Lipitor and did not have an agreement with any company to produce it.
GIA report: Global diabetes diagnostics market to reach $26 billion by 2015
SAN JOSE, Calif. — Global Industry Analysts on Wednesday released its report on the future growth of the diabetes diagnostics market.
In "Diabetes Diagnostics: A Global Strategic Business Report," GIA projected that the global market for diabetes diagnostics is expected to reach $26 billion by 2015. GIA noted that the United States is the largest regional market, followed by Europe. The report also noted that the increasing number of diabetics worldwide will prompt boosts in certain segments, including blood-glucose test strips and meters.
GIA also noted that as more diabetics seek instant results when testing their blood-glucose levels, technological advances and self-monitoring are factors that will drive diabetes product categories.
The report also provided annual sales estimates and projections for the global diabetes diagnostics market for the years 2007 through 2015 for the United States, Canada, Japan, Europe, Asia-Pacific, Latin America and more.
Click here to view the full report.